Aktis Oncology Reports Revenue Growth but Increased Net Loss in Q2 2026

Aktis Oncology, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending June 30, 2026. The company generated collaboration revenue of $3.4 million for the three months ended June 30, 2026, a substantial increase from $1.6 million in the same period last year. For the first half of 2026, collaboration revenue reached $6.6 million, compared to $3.0 million for the first half of 2025. Despite this revenue growth, Aktis reported a net loss of $24.1 million for the second quarter of 2026, up from a loss of $18.1 million in the prior year, and a total net loss of $42.5 million for the first half of 2026, compared to $33.1 million for the same period in 2025.

The company’s operating expenses also increased significantly, totaling $32.3 million for the second quarter of 2026, compared to $22.6 million in the same quarter of 2025. This rise was primarily driven by higher research and development costs, which amounted to $25.3 million in the latest quarter, reflecting ongoing clinical trials and increased employee-related expenses. General and administrative expenses also rose to $7.0 million, up from $3.9 million, largely due to increased headcount and costs associated with operating as a public company following its initial public offering (IPO) in January 2026.

Aktis completed its IPO in January 2026, raising approximately $334.4 million in net proceeds, which has bolstered its cash position. As of June 30, 2026, the company reported cash, cash equivalents, and marketable securities totaling $517.3 million, a significant increase from $230.3 million at the end of 2025. This financial cushion is expected to support the company’s operations into 2029, allowing it to continue advancing its clinical programs and expanding its operational capabilities.

In terms of operational metrics, Aktis is focused on advancing its lead product candidates, [225Ac]Ac-AKY-1189 and [225Ac]Ac-AKY-2519, through clinical trials. The company is also working on expanding its miniprotein radioconjugate platform and establishing a robust supply chain for critical radioisotopes. As of the latest filing, Aktis has not yet generated revenue from product sales, and its future revenue generation will depend on the successful development and regulatory approval of its product candidates.

Looking ahead, Aktis anticipates continued increases in both research and development and general administrative expenses as it scales its operations and pursues additional product candidates. The company remains focused on securing additional funding through equity offerings, collaborations, or other strategic arrangements to support its growth strategy. However, it acknowledges the inherent risks and uncertainties in the biotechnology sector, particularly regarding the successful development and commercialization of its product candidates.